Darius Cameron Wilson

TL;DR: In patients presenting to the ED with a suspected infection, the blood biomarker MR-proADM could most accurately identify the likelihood of further disease progression and incorporation into an early sepsis management protocol may aid rapid decision-making.

TL;DR: MR-proADM identifies disease severity and treatment response more accurately than established biomarkers and scores, adding additional information to facilitate rapid clinical decision-making and improve personalised sepsis treatment.

TL;DR: The early identification of patients likely to develop severe clinical symptoms requiring subsequent hospitalisation, as well as the safe discharge of those already hospitalised, may be of particular importance in regions where healthcare systems are used to full capacity.

TL;DR: Patients with low severity signs of infection but high MR-proADM concentrations had an increased likelihood of subsequent disease progression, delayed antibiotic administration or intensive care (ICU) admission, and Appropriate triage decisions and the rapid use of antibiotics may constitute initial steps in escalating or intensifying early treatment strategies.

TL;DR: Results suggest that initially high or increasing MR-proADM concentrations may help to identify patients with a high risk of progression towards sepsis-related multiple organ failure and play a significant role in driving the development of further organ dysfunction, as described previously.